[Immunological evaluation for CML and its possibility for an immunotherapy]

Area of Science:

• Oncology
• Immunology
• Hematology

Context:

• Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome and BCR-ABL fusion gene.
• The immune system plays a role in CML control, with T cell responses observed in patients treated with IFN-alpha or leukemic dendritic cells.
• Current first-line therapy, imatinib mesylate, targets BCR-ABL but does not eliminate CML stem cells.

Purpose:

• To review the innate and adaptive immune responses in CML.
• To explore the potential of combining imatinib therapy with immunotherapy for CML treatment.
• To identify strategies for enhancing immunity in imatinib-treated CML patients.

Summary:

• Oligoclonal T cell responses were noted in CML patients treated with IFN-alpha or leukemic dendritic cells.
• Leukemic antigen peptide therapy has shown immune and clinical responses in chronic phase CML (CP-CML).
• Imatinib, a tyrosine kinase inhibitor, is effective but cannot eradicate CML stem cells, necessitating alternative or complementary strategies.

Impact:

• Combining imatinib with immunotherapy presents a promising approach to overcome CML stem cell resistance.
• Enhancing immune responses could lead to more effective and durable CML treatments.
• This review highlights the potential of immunotherapeutic strategies for imatinib-refractory CML.